---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057171"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:50:18.153586+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June

## Summary
- Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.
- Net loss $9.8M (vs $11.0M YoY); R&D $6.8M, G&A $3.3M, both down vs prior year.
- SIM0505 (CDH6 ADC) granted FDA Fast Track for platinum-resistant ovarian cancer; Phase 1 dose optimization initiated May 2026.
- Initial Phase 1 dose escalation data for SIM0505 to be presented at ASCO 2026 on June 1, 2026, including US and China patients.
- LNCB74 (B7-H4 ADC) Phase 1 dose escalation enrollment ongoing; trial progress update expected in H2 2026.

## SEC filing metadata
- accession: 0001104659-26-057171
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/0001104659-26-057171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926057171/nxtc-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057171
- JSON: https://secwatch.observer/filing/0001104659-26-057171.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.